(Q39906058)

English

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

phase II clinical trial

0 references

chemoradiotherapy

0 references

magnetic resonance imaging

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Andrew Wotherspoon

6

object named as

Andrew Wotherspoon

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

10

object named as

Ian Chau

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Yolanda Barbachano

2

object named as

Yolanda Barbachano

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

4

object named as

Jacqui R Oates

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

9

object named as

Niall C Tebbutt

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Yu Jo Chua

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Diana Tait

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Alison Massey

8

0 references

publication date

25 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

241-248

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Local recurrence after mesorectal excision for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative versus postoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with preoperative radiotherapy in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The TME Trial After a Median Follow-up of 6 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Thin section MRI in multidisciplinary pre-operative decision making for patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Techniques and trouble-shooting in high spatial resolution thin slice MRI for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970381-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70381-X

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39906058&oldid=2144897225"